Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Bleeding risk following systemic fluconazole or topical azoles in patients with atrial fibrillation on apixaban, rivaroxaban or dabigatran

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Does Subclinical Hypothyroidism Add Any Symptoms? evidence from a Danish population-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Antimycotic treatment of oral candidiasis in warfarin users

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Incidence rates of dilated cardiomyopathy in adult first-degree relatives versus matched controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Left atrial contractile strain predicts recurrence of atrial tachyarrhythmia after catheter ablation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk of out-of-hospital cardiac arrest in antidepressant drug users

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Global and regional wall motion abnormalities and incident heart failure in the general population

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Bleeding safety in relation to use of systemic fluconazole and topical azoles among patients with atrial fibrillation treated with apixaban, rivaroxaban, or dabigatran is insufficiently explored, despite clinical relevance and several reports suggesting associations.

METHODS: Using nationwide Danish registers, we identified patients with atrial fibrillation initiated on apixaban, rivaroxaban, or dabigatran from 2012-2018. We investigated associations between bleeding incidents and systemic fluconazole or topical azole treatment using a case-crossover design with 30-day exposure windows and reported odds ratios (OR) with 95% confidence intervals (CI).

RESULTS: We included 32,340 (36%), 32,409 (36%), and 24,940 (28%) patients initiated on apixaban, rivaroxaban, and dabigatran, respectively. Patients on apixaban were older (median age: 77 years; interquartile range [IQR] 70-84) compared with rivaroxaban users (median age: 75 years; IQR 68-82) and patients on dabigatran (median age: 73 years; IQR 66-80). Apixaban users had a significantly increased risk of bleeding following exposure to systemic fluconazole: odds ratio (OR) 3.5; 95% confidence interval (CI), 1.4-10.6. No increased risk was found among rivaroxaban and dabigatran users: ORs of 0.9 (95% CI, 0.2-3.0) and 1.7 (95% CI, 0.5-5.6), respectively. As to bleeding risk pertaining to topical azole exposure among apixaban, rivaroxaban, and dabigatran users, no association was found, with corresponding ORs of 0.8 (95% CI, 0.5-1.3); 1.3 (95% CI, 0.9-2.1); and 1.2 (95% CI 0.8-1.8), respectively.

CONCLUSION: In patients with atrial fibrillation on either apixaban, rivaroxaban, or dabigatran, an association between an elevated bleeding risk and use of systemic fluconazole was found among patients on apixaban. We found no increased risk of bleeding following co-exposure to topical azoles.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Medicine
Vol/bind135
Udgave nummer5
Sider (fra-til)595-602.e5
ISSN0002-9343
DOI
StatusUdgivet - maj 2022

Bibliografisk note

Copyright © 2021. Published by Elsevier Inc.

ID: 69546904